WFS1 and amyotrophic lateral sclerosis: Riluzole, one of the few drugs approved for the treatment of amyotrophic lateral sclerosis (ALS), regulated aberrant glutamate transporter expression in Wfs1-deficient cerebral organoids, thereby restoring synapse formation and functionality.